The diagnosis of neurocognitive diseases is an important health issue for patients, families and healthcare professionals. The need to develop rapid, high-performance screening tools would improve access to care. The Clock Drawing Test (CDT) is widely used and validated with the older adults, and its digital version is becoming increasingly widespread. We propose to confirm its validity in a population of old patients hospitalized in a geriatric unit, and secondly to verify its performance in comparison with the reference diagnosis made by a specialized team in a memory consultation. CDTs were collected from older hospitalized patients, both in paper form and digitally on a touchscreen tablet. The results show good agreement between the paper and digital versions (kappa coefficient = 0.81). Sensitivity and specificity of the digital CDT were 0.84 and 0.59 respectively for the diagnosis of major cognitive disorders. The corresponding values were 0.72 and 0.59 for the diagnosis of mild neurocognitive disorders. User questionnaires indicate that older participants find the digital tablet easy to use. However, they prefer to use paper, even if they are open to learning how to use the tablet.
Neurocognitive diseases are diagnosed in specialized centers such as memory clinics, where the waiting time can be long. The reference assessment involves a battery of tests carried out by a specialized team. Facilitating screening in primary care using new technologies could make it possible to appropriately direct care pathways towards specialist care. This work aimed to set up a battery of questionnaires, cognitive and manual dexterity tests on a digital tablet to screen people with cognitive impairment. Three groups of people are recruited from a memory consultation: people with major neurocognitive disorders, people with mild neurocognitive disorders and people with no cognitive impairment. Initial results in geriatric settings show that the digital tablet assessment test is feasible and well accepted, but that manual dexterity assessment needs to be adapted to the bodily particularities of the very old.
Background/Objectives: Mild neurocognitive disorder (mNCD) is a state of vulnerability, in which individuals exhibit cognitive deficits identified by cognitive testing, which do not interfere with their ability to independently perform in daily activities. New touchscreen tools had to be designed for cognitive assessment and had to be at an advanced stage of development but their clinical relevance is still unclear. We aimed to identify digital tools used in the diagnosis of mNCD and assess the diagnostic performance of these tools. Methods: In a systematic review, we searched 4 databases for articles (PubMed, Embase, Web of science, IEEE Xplore). From 6516 studies retrieved, we included 50 articles in the review in which a touchscreen tool was used to assess cognitive function in older adults. Study quality was assessed using the QUADAS-II scale. Data from 34 articles were appropriate for meta-analysis and were analyzed using the bivariate random-effects method (STATA software version 19). Results: The 50 articles in the review totaled 5974 participants and the 34 in the meta-analysis, 4500 participants. Pooled sensitivity and specificity were 0.81 (95%CI: 0.78 to 0.84) and 0.83 (95%CI: 0.79 to 0.86), respectively. High heterogeneity among the studies led us to examine test performance across key characteristics in a subgroup analysis. Tests that are short and self-administered on a touchscreen tablet perform as well as longer tests administered by an assessor or on a fixed device. Conclusions: Cognitive testing with a touchscreen tablet is appropriate for screening for mNCD. Further studies are needed to determine their clinical utility in screening for mNCD in primary care settings and referral to specialized care. This research received no external funding and is registered with PROSPERO under the number CRD42022358725.
Introduction: Alzheimer's disease (AD) is the first cause of dementia worldwide without any current curative treatment. Facing an increasing prevalence and its associated costs, AD represents a public health challenge. Usual diagnostic methods still rely on extended interviews and paper tests provided by an exterior examiner. We aim to create a novel, quick cognitive-screening tool on a numerical tablet. Methods: This pilot program, built and edited with Unity ® , runs on Android ® for the Samsung Galaxy Tab S7 FE ® . Composed of seven tasks inspired by the Mini-Mental Status Examination and the Montréal Cognitive Assessment, it browses several cognitive functions. The architectural design of this tablet application is distinguished by its multifaceted capabilities, encompassing not only seamless offline functionality but also a mechanism to ensure the singularity of data amalgamated from diverse sites. Additionally, a paramount emphasis is placed on safeguarding the confidentiality of patient information in the healthcare domain. Furthermore, the application empowers individual site managers to access and peruse specific datasets, enhancing their operational efficacy and decision-making processes. We performed a preliminary usability assessment among young, healthy subjects. Results: Twenty-four participants were included with a final F-SUS ‘excellent’ score. Participants perceived the tool as simple to use and achieved the test in a mean time of 142 s. No technical errors occurred. Conclusion: These preliminary results suggest that our new assessment on a numerical tablet might be usable and acceptable for a short cognitive screening but requires further studies among older populations.
La maladie d'Alzheimer représente un défi médical, social et économique dans un contexte de vieillissement de la population. Les outils de dépistage et de diagnostic actuels reposent sur des hétéro-évaluations papier. De nombreux outils numériques non immersifs (tablettes, smartphones, écrans tactiles) ont été publiés avec de bonnes performances diagnostiques. D'autres évaluations en réalité virtuelle immersive ont montré des résultats similaires.Le projet AlzVR propose la création de nouveaux outils dans la maladie d'Alzheimer dans une approche centrée sur l'utilisateur. Se basant sur les tests MMSE et MoCA, nous avons conçu une auto-évaluation sur tablette tactile. Une étude multicentrique est en cours avec inclusion de sujets sains, atteints de trouble cognitif léger, ou d'une maladie d'Alzheimer. Elle évalue un programme multimodal non immersif, incluant notre outil. Les résultats préliminaires d'utilisabilité (en population jeune et âgée) et d'efficacité des tâches cognitives sont encourageants. Nous avons également créé deux outils en réalité virtuelle immersive dont une version innovante associant deux nouvelles modalités sensorielles pour l'évaluation cognitive à savoir l'olfaction et le retour haptique. Ces environnements multi-sensoriels permettront d'évaluer des fonctions cognitives jusqu'alors non explorées par les outils digitaux usuels. Nous espérons, à ce titre, débuter sous peu des études cliniques.